Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 16/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1584522 | 0.88 | FFAR1 (0.61) | FFAR1PPARG | |
| SCHEMBL12708086 | 0.86 | FFAR1 (0.54) | FFAR1PPARG | |
| SCHEMBL12707964 | 0.85 | FFAR1 (0.64) | FFAR1PPARG | |
| SCHEMBL12707808 | 0.81 | FFAR1 (0.57) | FFAR1PPARGGABRA1GABRG2GABRB3 | |
| SCHEMBL1584998 | 0.78 | FFAR1 (0.40) | FFAR1PPARG | |
| SCHEMBL1585000 | 0.78 | FFAR1 (0.40) | FFAR1PPARG | |
| SCHEMBL5646973 | 0.78 | FFAR1 (0.53) | FFAR1PPARGGABRA1GABRG2GABRB3 | |
| SCHEMBL1584822 | 0.74 | FFAR1 (0.77) | FFAR1PPARGGABRA1GABRG2GABRB3 | |
| SCHEMBL183440 | 0.73 | FFAR1 (0.48) | FFAR1PPARGGABRA1GABRG2GABRB3 | |
| SCHEMBL1584028 | 0.72 | FFAR1 (0.64) | FFAR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486005-B1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| US-8288404-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2486005-A1 | PYRROLIDINE GPR40 MODULATORS | Bristol-Myers Squibb Company (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044073-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR27 | FFAR1 37/4885PPARG 69/4885GABRA1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.